Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib vs Chemotherapy in MET Exon 14 Skipping NSCLC
NCT04322578Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Mar 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of crizotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival at 36 months. Started Mar 2020; status: recruiting.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04322578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322578.